Krystal Biotech, Inc. (KRYS) financial statements (2021 and earlier)
Company profile
| Business Address |
2100 WHARTON STREET PITTSBURGH, PA 15203 |
| State of Incorp. | |
| Fiscal Year End | December 31 |
| SIC | 2836 - Biological Products, Except Diagnostic Substances (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in millions)
| 12/31/2020 | 12/31/2019 | 12/31/2017 | |||
|---|---|---|---|---|---|
| ASSETS | |||||
| Current Assets | |||||
| Cash, cash equivalents, and short-term investments, including: | 271 | 194 | 50 | ||
| Cash and cash equivalents | 268 | 188 | 50 | ||
| Short-term investments | 3 | 6 | |||
| Other undisclosed cash, cash equivalents, and short-term investments | 0 | 0 | |||
| Prepaid expense | 0 | ||||
| Other current assets | 0 | ||||
| Other undisclosed current assets | 4 | 2 | |||
| Total current assets: | 275 | 196 | 50 | ||
| Noncurrent Assets | |||||
| Operating lease, right-of-use asset | 3 | 3 | ✕ | ||
| Property, plant and equipment | 31 | 8 | 0 | ||
| Long-term investments and receivables | 0 | ||||
| Long-term investments | 0 | ||||
| Other noncurrent assets | 2 | 1 | |||
| Total noncurrent assets: | 36 | 13 | 0 | ||
| TOTAL ASSETS: | 311 | 209 | 50 | ||
| LIABILITIES AND EQUITY | |||||
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 3 | 1 | 0 | ||
| Accounts payable | 2 | 1 | 0 | ||
| Accrued liabilities | 1 | 0 | 0 | ||
| Debt | 0 | ||||
| Other liabilities | 0 | 0 | |||
| Other undisclosed current liabilities | 13 | 2 | 0 | ||
| Total current liabilities: | 15 | 3 | 1 | ||
| Noncurrent Liabilities | |||||
| Long-term debt and lease obligation | 3 | 3 | |||
| Operating lease, liability | 3 | 3 | ✕ | ||
| Other undisclosed noncurrent liabilities | (3) | ||||
| Total noncurrent liabilities: | 3 | 3 | |||
| Total liabilities: | 19 | 6 | 1 | ||
| Stockholders' equity | |||||
| Stockholders' equity attributable to parent | 292 | 203 | 49 | ||
| Additional paid in capital | 363 | 242 | 59 | ||
| Accumulated other comprehensive income | 0 | 0 | |||
| Accumulated deficit | (71) | (39) | (9) | ||
| Total stockholders' equity: | 292 | 203 | 49 | ||
| TOTAL LIABILITIES AND EQUITY: | 311 | 209 | 50 | ||
Income statement (P&L) ($ in millions)
| 12/31/2020 | 12/31/2019 | 12/31/2017 | ||
|---|---|---|---|---|
| Operating expenses | (33) | (22) | (5) | |
| Other undisclosed operating income | 0 | 0 | ||
| Operating loss: | (33) | (22) | (5) | |
| Nonoperating expense | (3) | |||
| Net loss: | (33) | (22) | (8) | |
| Other undisclosed net income attributable to parent | 1 | 3 | ||
| Net loss available to common stockholders, diluted: | (32) | (19) | (8) | |
Comprehensive Income ($ in millions)
| 12/31/2020 | 12/31/2019 | 12/31/2017 | ||
|---|---|---|---|---|
| Net loss: | (33) | (22) | (8) | |
| Comprehensive loss: | (33) | (22) | (8) | |
| Other undisclosed comprehensive income, net of tax, attributable to parent | 1 | 3 | ||
| Comprehensive loss, net of tax, attributable to parent: | (32) | (19) | (8) | |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.